Goldman resumed coverage on Sema4 Holdings Corp with a new price target
$SMFR
Retail: Computer Software & Peripheral Equipment
Technology
Goldman resumed coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $3.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/7/2022 | $3.00 → $1.00 | Buy → Neutral | Goldman |
| 8/16/2022 | $4.00 → $2.00 | Buy → Hold | Jefferies |
| 6/2/2022 | $3.50 | Buy | Goldman |
| 11/19/2021 | $12.00 | Buy | Goldman Sachs |
| 10/8/2021 | $12.00 | Buy | BTIG Research |
| 9/30/2021 | $13.00 | Outperform | Cowen & Co. |
| 9/24/2021 | $13.00 | Buy | Jefferies |
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
144 - GeneDx Holdings Corp. (0001818331) (Subject)
10-Q - GeneDx Holdings Corp. (0001818331) (Filer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity
STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai
Goldman downgraded Sema4 Holdings Corp from Buy to Neutral and set a new price target of $1.00 from $3.00 previously
Jefferies downgraded Sema4 Holdings Corp from Buy to Hold and set a new price target of $2.00 from $4.00 previously
Goldman resumed coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $3.50
STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position. Mr. Feeley, who has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022, will also continue to lead all key operational aspects of the Company. "As we shared during our recent earnings call, our new management team is committed to profitable growth, efficiency, and scale. Kevin's broad industry experience and successful financial leadership of GeneDx during an accelerated phase of commercial
Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4's Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. "We are extremely thankful fo
SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SC 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Gainers CinCor Pharma, Inc. (NASDAQ:CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. Apexigen, Inc. (NASDAQ:APGN) jumped 111% to $1.99 after climbing more than 10% on Friday. Amryt Pharma plc (NASDAQ:AMYT) gained 106.7% to $14.49 after Chiesi Farmaceutici announced it will acquire the company for $14.50 per ADS plus contingent value rights of up to an additional $2.50 per ADS. Albireo Pharma, Inc. (NASDAQ:ALBO) shares climbed 92.9% to $44.03 after Ipsen announced it will acquire the company for $42 per share plus a contingent value right of $10 per share. Duck Creek Technologies, Inc. (NASDAQ:DCT) gained 47% to $19.1
Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care.